{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T04:03:32Z","timestamp":1791000212037,"version":"4.1.0"},"reference-count":66,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>The process of developing therapies to treat rare diseases is fraught with financial, regulatory, and logistical challenges that have limited our ability to build effective treatments. Recently, a novel type of therapy called antisense therapy has shown immense potential for the treatment of rare diseases, particularly through single-patient N-of-1 trials. Several N-of-1 antisense therapies have been developed recently for rare diseases, including the landmark study of milasen. In response to the success of N-of-1 antisense therapy, the Food and Drug Administration (FDA) has developed unique guidelines specifically for the development of antisense therapy to treat N-of-1 rare diseases. This policy change establishes a strong foundation for future therapy development and addresses some of the major limitations that previously hindered the development of therapies for rare diseases.<\/jats:p>","DOI":"10.3390\/genes15070821","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T05:33:28Z","timestamp":1718948008000},"page":"821","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Preparing for Patient-Customized N-of-1 Antisense Oligonucleotide Therapy to Treat Rare Diseases"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2696-265X","authenticated-orcid":false,"given":"Harry","family":"Wilton-Clark","sequence":"first","affiliation":[{"name":"Department of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2R3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, Faculty of Science, University of Alberta, Edmonton, AB T6G 2R3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6672-6742","authenticated-orcid":false,"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2R3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1028545","DOI":"10.3389\/fpubh.2022.1028545","article-title":"Rare Disease Emerging as a Global Public Health Priority","volume":"10","author":"Chung","year":"2022","journal-title":"Front. Public Health"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/nat.2021.0039","article-title":"Preparing N-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical Perspectives","volume":"32","author":"Synofzik","year":"2022","journal-title":"Nucleic Acid Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41431-019-0508-0","article-title":"Estimating Cumulative Point Prevalence of Rare Diseases: Analysis of the Orphanet Database","volume":"28","author":"Lambert","year":"2020","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s10928-023-09859-7","article-title":"The Future of Rare Disease Drug Development: The Rare Disease Cures Accelerator Data Analytics Platform (RDCA-DAP)","volume":"50","author":"Barrett","year":"2023","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1111\/bcp.15350","article-title":"Addressing the Challenges of Novel Therapies in Rare Diseases with Mechanistic Perspectives: Missed Opportunities or the Way Forward?","volume":"88","author":"Mifsud","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"(2019). The Lancet Diabetes & Endocrinology Spotlight on Rare Diseases. Lancet Diabetes Endocrinol., 7, 75.","DOI":"10.1016\/S2213-8587(19)30006-3"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-023-02635-3","article-title":"Strategic Discussion on Funding and Access to Therapies Targeting Rare Diseases in Spain: An Expert Consensus Paper","volume":"18","author":"Zozaya","year":"2023","journal-title":"Orphanet. J. Rare Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1001\/jama.2020.1166","article-title":"Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009\u20132018","volume":"323","author":"Wouters","year":"2020","journal-title":"JAMA"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Chirmule, N., Feng, H., Cyril, E., Vivek Ghalsasi, V., and Chakraborty Choudhury, M. (2024). Orphan Drug Development: Challenges, Regulation, and Success Stories. J. Biosci., 49.","DOI":"10.1007\/s12038-024-00425-y"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1001\/jamapediatrics.2020.5801","article-title":"Personalized (N-of-1) Trials: A Primer","volume":"175","author":"Davidson","year":"2021","journal-title":"JAMA Pediatr."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1261\/rna.653607","article-title":"Antisense-Mediated Exon Skipping: A Versatile Tool with Therapeutic and Research Applications","volume":"13","year":"2007","journal-title":"RNA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"869","DOI":"10.3233\/JND-200560","article-title":"Emerging Oligonucleotide Therapeutics for Rare Neuromuscular Diseases","volume":"8","author":"Aoki","year":"2021","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s43856-023-00419-1","article-title":"Possibilities and Limitations of Antisense Oligonucleotide Therapies for the Treatment of Monogenic Disorders","volume":"4","author":"Lauffer","year":"2024","journal-title":"Commun. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1017\/erm.2019.5","article-title":"Recent Advancements in Exon-Skipping Therapies Using Antisense Oligonucleotides and Genome Editing for the Treatment of Various Muscular Dystrophies","volume":"21","author":"Hwang","year":"2019","journal-title":"Expert Rev. Mol. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/oli.2008.0161","article-title":"Therapeutic Potential of Splice-Switching Oligonucleotides","volume":"19","author":"Bauman","year":"2009","journal-title":"Oligonucleotides"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.1093\/nar\/gkw533","article-title":"Splice-Switching Antisense Oligonucleotides as Therapeutic Drugs","volume":"44","author":"Havens","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Pauli, A., Montague, T.G., Lennox, K.A., Behlke, M.A., and Schier, A.F. (2015). Antisense Oligonucleotide-Mediated Transcript Knockdown in Zebrafish. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0139504"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne Muscular Dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Oberemok, V.V., Laikova, K.V., Repetskaya, A.I., Kenyo, I.M., Gorlov, M.V., Kasich, I.N., Krasnodubets, A.M., Gal\u2019chinsky, N.V., Fomochkina, I.I., and Zaitsev, A.S. (2018). A Half-Century History of Applications of Antisense Oligonucleotides in Medicine, Agriculture and Forestry: We Should Continue the Journey. Molecules, 23.","DOI":"10.20944\/preprints201804.0366.v1"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2165\/00003495-199957030-00010","article-title":"Fomivirsen","volume":"57","author":"Perry","year":"1999","journal-title":"Drugs"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4103\/aian.AIAN_298_17","article-title":"Recent Advances in Antisense Oligonucleotide Therapy in Genetic Neuromuscular Diseases","volume":"21","author":"Verma","year":"2018","journal-title":"Ann. Indian Acad. Neurol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2147\/VHRM.S191965","article-title":"Mipomersen in Familial Hypercholesterolemia: An Update on Health-Related Quality of Life and Patient-Reported Outcomes","volume":"18","author":"Alur","year":"2022","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","article-title":"Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS","volume":"387","author":"Miller","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1756285618754459","DOI":"10.1177\/1756285618754459","article-title":"Nusinersen for Spinal Muscular Atrophy","volume":"11","author":"Wurster","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s40265-021-01512-2","article-title":"Casimersen: First Approval","volume":"81","author":"Shirley","year":"2021","journal-title":"Drugs"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1358\/dot.2019.55.10.3045038","article-title":"Viltolarsen for the Treatment of Duchenne Muscular Dystrophy","volume":"55","author":"Roshmi","year":"2019","journal-title":"Drugs Today"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2147\/DDDT.S97635","article-title":"Eteplirsen in the Treatment of Duchenne Muscular Dystrophy","volume":"11","author":"Lim","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1089\/nat.2021.0043","article-title":"Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-Human, Multicenter, Two-Part, Open-Label, Phase 1\/2 Trial","volume":"32","author":"Servais","year":"2022","journal-title":"Nucleic Acid. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Moumn\u00e9, L., Marie, A.C., and Crouvezier, N. (2022). Oligonucleotide Therapeutics: From Discovery and Development to Patentability. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14020260"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.drudis.2017.01.013","article-title":"Safety of Antisense Oligonucleotide and SiRNA-Based Therapeutics","volume":"22","author":"Chi","year":"2017","journal-title":"Drug Discov. Today"},{"key":"ref_32","unstructured":"(2024, May 15). Antisense Oligonucleotides: Basic Concepts and Mechanisms | Molecular Cancer Therapeutics | American Association for Cancer Research. Available online: https:\/\/aacrjournals.org\/mct\/article\/1\/5\/347\/233708\/Antisense-Oligonucleotides-Basic-Concepts-and."},{"key":"ref_33","unstructured":"(2023, September 26). Milasen: Genetic Diagnosis to Custom Drug, in under 1 Year\u2014Boston Children\u2019s Answers. Available online: https:\/\/answers.childrenshospital.org\/milasen-batten-disease\/."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","article-title":"Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease","volume":"381","author":"Kim","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41582-019-0138-8","article-title":"Therapeutic Landscape for Batten Disease: Current Treatments and Future Prospects","volume":"15","author":"Johnson","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1177\/0883073813493665","article-title":"Batten Disease: Clinical Aspects, Molecular Mechanisms, Translational Science, and Future Directions","volume":"28","author":"Dolisca","year":"2013","journal-title":"J. Child Neurol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1038\/s41591-020-0986-1","article-title":"Therapeutic Efficacy of Antisense Oligonucleotides in Mouse Models of CLN3 Batten Disease","volume":"26","author":"Centa","year":"2020","journal-title":"Nat. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.omtn.2023.05.025","article-title":"Protracted CLN3 Batten Disease in Mice That Genetically Model an Exon-Skipping Therapeutic Approach","volume":"33","author":"Centa","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/s41586-023-06277-0","article-title":"A Framework for Individualized Splice-Switching Oligonucleotide Therapy","volume":"619","author":"Kim","year":"2023","journal-title":"Nature"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3389\/fneur.2017.00570","article-title":"Two Novel Mutations Associated with Ataxia-Telangiectasia Identified Using an Ion AmpliSeq Inherited Disease Panel","volume":"8","author":"Kuznetsova","year":"2017","journal-title":"Front. Neurol."},{"key":"ref_41","first-page":"1","article-title":"Ataxia Telangiectasia: A Review","volume":"11","author":"Wright","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1212\/WNL.0b013e3181af33bd","article-title":"Clinical Spectrum of Ataxia-Telangiectasia in Adulthood","volume":"73","author":"Verhagen","year":"2009","journal-title":"Neurology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.2147\/JMDH.S295486","article-title":"Multidisciplinary Management of Ataxia Telangiectasia: Current Perspectives","volume":"14","author":"Wright","year":"2021","journal-title":"J. Multidiscip. Health"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"14663","DOI":"10.1002\/cam4.6075","article-title":"Development of Cancer Surveillance Guidelines in Ataxia Telangiectasia: A Delphi-based Consensus Survey of International Experts","volume":"12","author":"Neves","year":"2023","journal-title":"Cancer Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/mds.29645","article-title":"Long-Term Nicotinamide Riboside Use Improves Coordination and Eye Movements in Ataxia Telangiectasia","volume":"39","author":"Presterud","year":"2024","journal-title":"Mov. Disord."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"6007","DOI":"10.1073\/pnas.0608616104","article-title":"Correction of Prototypic ATM Splicing Mutations and Aberrant ATM Function with Antisense Morpholino Oligonucleotides","volume":"104","author":"Du","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","unstructured":"(2024, January 28). Custom Genetic Treatments: Seeking a Path Forward\u2014Boston Children\u2019s Answers. Available online: https:\/\/answers.childrenshospital.org\/custom-genetic-treatments\/."},{"key":"ref_48","unstructured":"(2024, May 26). Home\u2014VALERIA ASSOCIATION. Available online: https:\/\/www.valerias.org\/en."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e146090","DOI":"10.1172\/jci.insight.146090","article-title":"Antisense Oligonucleotide Therapy for KCNT1 Encephalopathy","volume":"7","author":"Burbano","year":"2022","journal-title":"JCI Insight"},{"key":"ref_50","unstructured":"(2024, May 26). Gene Treatment for Rare Epilepsy Causes Brain Side Effect in 2 Children\u2014The New York Times. Available online: https:\/\/www-nytimes-com.login.ezproxy.library.ualberta.ca\/2022\/10\/26\/health\/gene-treatment-epilepsy-antisense-brain.html."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/mds.28359","article-title":"Hydrocephalus Complicating Intrathecal Antisense Oligonucleotide Therapy for Huntington\u2019s Disease","volume":"36","author":"Stoker","year":"2021","journal-title":"Mov. Disord."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1212\/WNL.0000000000006502","article-title":"Evidence in Focus: Nusinersen Use in Spinal Muscular Atrophy Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology","volume":"91","author":"Michelson","year":"2018","journal-title":"Neurology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pediatrneurol.2016.02.011","article-title":"Clinical and Surgical Factors Associated with Increased Epilepsy Risk in Children with Hydrocephalus","volume":"59","author":"Tully","year":"2016","journal-title":"Pediatr. Neurol."},{"key":"ref_54","unstructured":"(2024, May 26). Abstract Details | ASGCT Annual Meeting. Available online: https:\/\/annualmeeting.asgct.org\/abstracts\/abstract-details?abstractId=98297."},{"key":"ref_55","unstructured":"(2024, May 26). Susannah\u2019s Superhero Story\u2014KIF1A. Available online: https:\/\/www.kif1a.org\/blog\/susannahs-superhero-story\/."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Nair, A., Greeny, A., Rajendran, R., Abdelgawad, M.A., Ghoneim, M.M., Raghavan, R.P., Sudevan, S.T., Mathew, B., and Kim, H. (2023). KIF1A-Associated Neurological Disorder: An Overview of a Rare Mutational Disease. Pharmaceuticals, 16.","DOI":"10.3390\/ph16020147"},{"key":"ref_57","unstructured":"(2024, May 26). They Created a Drug for Susannah. Available online: https:\/\/www-nytimes-com.login.ezproxy.library.ualberta.ca\/2022\/12\/19\/health\/rare-disease-genetic-treatments.html."},{"key":"ref_58","unstructured":"IND (2024, May 05). Submissions for Individualized Antisense Oligonucleotide Drug Products: Administrative and Procedural Recommendations Guidance for Sponsor-Investigators | FDA, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/ind-submissions-individualized-antisense-oligonucleotide-drug-products-administrative-and-procedural."},{"key":"ref_59","unstructured":"(2024, May 16). Nonclinical Testing of Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases Guidance for Sponsor-Investigators | FDA, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/nonclinical-testing-individualized-antisense-oligonucleotide-drug-products-severely-debilitating-or."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1358\/dot.2021.57.12.3352740","article-title":"Casimersen for Duchenne Muscular Dystrophy","volume":"57","author":"Yokota","year":"2021","journal-title":"Drugs Today"},{"key":"ref_61","unstructured":"(2024, May 16). Investigational New Drug Application Submissions for Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases: Chemistry, Manufacturing, and Controls Recommendations, Guidance for Sponsor-Investigators | FDA, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/investigational-new-drug-application-submissions-individualized-antisense-oligonucleotide-drug."},{"key":"ref_62","unstructured":"(2022, December 21). An Open-Label Extension Study for Patients with Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051 (Vesleteplirsen)\u2014Full Text View\u2014ClinicalTrials, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03675126?term=NCT03675126&draw=2&rank=1."},{"key":"ref_63","unstructured":"(2022, December 21). Sarepta Therapeutics Provides Update on SRP-5051 for the Treatment of Duchenne Muscular Dystrophy | Sarepta Therapeutics, Inc. Available online: https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-therapeutics-provides-update-srp-5051-treatment-duchenne."},{"key":"ref_64","unstructured":"(2024, May 18). IND Submissions for Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases: Clinical Recommendations |FDA, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/ind-submissions-individualized-antisense-oligonucleotide-drug-products-severely-debilitating-or-life."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A Simple Practice Guide for Dose Conversion between Animals and Human","volume":"7","author":"Nair","year":"2016","journal-title":"J. Basic Clin. Pharm."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Sewing, S., Roth, A.B., Winter, M., Dieckmann, A., Bertinetti-Lapatki, C., Tessier, Y., McGinnis, C., Huber, S., Koller, E., and Ploix, C. (2017). Assessing Single-Stranded Oligonucleotide Drug-Induced Effects in Vitro Reveals Key Risk Factors for Thrombocytopenia. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0187574"}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/15\/7\/821\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:02:11Z","timestamp":1760108531000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/15\/7\/821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,21]]},"references-count":66,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["genes15070821"],"URL":"https:\/\/doi.org\/10.3390\/genes15070821","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,21]]}}}